This article covers major news from Fierce Pharma Asia, highlighting Merck and Kelun-Biotech's sac-TMT ADC's three positive Phase 3 trial results, str...
Takeda Pharmaceutical Company Limited's average price target has been increased from $19.2 to $19.3 by 11 analysts, with forecasts ranging from $15.4 ...
Neutral
The article titled "Eyes on Asia: BeOne Medicines, Takeda, GSK" is not accessible, as indicated by a "404 Error: Sorry, the page you requested cannot ...
Neutral
Takeda Pharmaceutical Company announced the completion of its SPOTLITE study, an observational study tracking real-world surgical outcomes for complex...